|
Adverse event
|
Any grade (cases)
|
Grade 3–4 (cases)
|
|---|
|
HAIC group
|
TACE group
|
P
|
HAIC group
|
TACE group
|
P
|
|---|
|
Total
|
35
|
41
|
0.110
|
13
|
27
|
0.007
|
|
Postembolization syndrome
|
|
Fever
|
7
|
30
|
< 0.001
|
0
|
8
|
0.006
|
|
Pain
|
30
|
27
|
0.219
|
1
|
1
|
1.000
|
|
Vomiting
|
21
|
18
|
0.371
|
4
|
1
|
0.190
|
|
Liver dysfunction
|
|
Elevated ALT level
|
27
|
38
|
0.017
|
1
|
16
|
< 0.001
|
|
Hypoalbuminemia
|
34
|
27
|
0.016
|
0
|
0
|
1.000
|
|
Hyperbilirubinemia
|
13
|
35
|
< 0.001
|
0
|
3
|
0.241
|
|
Systemic toxicity
|
|
Leukopenia
|
13
|
8
|
0.203
|
3
|
1
|
0.347
|
|
Neutropenia
|
6
|
6
|
1.000
|
0
|
1
|
1.000
|
|
Anemia
|
27
|
25
|
0.477
|
1
|
2
|
1.000
|
|
Thrombocytopenia
|
13
|
17
|
0.643
|
2
|
4
|
0.676
|
|
Anorexia
|
30
|
29
|
0.447
|
0
|
0
|
1.000
|
|
Diarrhea
|
12
|
1
|
0.001
|
1
|
0
|
0.481
|
|
Sensory neuropathy
|
9
|
1
|
0.006
|
1
|
0
|
0.481
|
|
Ascites/pleural effusion
|
2
|
3
|
1.000
|
1
|
2
|
1.000
|
|
Cholangitis
|
0
|
3
|
0.241
|
0
|
2
|
0.494
|
|
Hepatapostema
|
0
|
1
|
1.000
|
0
|
1
|
1.000
|
|
Hepatic failure
|
0
|
1
|
1.000
|
0
|
1
|
1.000
|
|
Renal failure
|
2
|
5
|
0.434
|
0
|
2
|
0.494
|
|
Gastrointestinal bleeding
|
1
|
2
|
1.000
|
1
|
2
|
1.000
|
-
AE adverse event; HAIC hepatic artery infusion chemotherapy; TACE transarterial chemoembolization; ALT alanine transaminase
-
P values were calculated using a two-sided Chi square test
